Kelly Elian

459 total citations
10 papers, 367 citations indexed

About

Kelly Elian is a scholar working on Oncology, Rheumatology and Surgery. According to data from OpenAlex, Kelly Elian has authored 10 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Rheumatology and 3 papers in Surgery. Recurrent topics in Kelly Elian's work include Cancer Treatment and Pharmacology (4 papers), Folate and B Vitamins Research (4 papers) and Esophageal and GI Pathology (3 papers). Kelly Elian is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Folate and B Vitamins Research (4 papers) and Esophageal and GI Pathology (3 papers). Kelly Elian collaborates with scholars based in Canada and United States. Kelly Elian's co-authors include L. John Hoffer, John Sarantopoulos, Andrew Brenner, Stacy L. Moulder, Razelle Kurzrock, N. Gabrail, Danielle R. B̀ouchard, Chandtip Chandhasin, Alain C. Mita and Kamalesh K. Sankhala and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Kelly Elian

9 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kelly Elian Canada	6	167	101	93	69	61	10	367
Joseph Molter United States	11	252 1.5×	120 1.2×	30 0.3×	40 0.6×	16 0.3×	13	488
Maritza E. Mayorga United States	12	219 1.3×	34 0.3×	41 0.4×	60 0.9×	32 0.5×	14	432
Ihab Abd‐Elrahman Israel	8	181 1.1×	51 0.5×	31 0.3×	68 1.0×	21 0.3×	11	443
Pang-ning Teng United States	13	329 2.0×	137 1.4×	23 0.2×	77 1.1×	43 0.7×	25	652
Paolo G. Montaldo Italy	14	447 2.7×	88 0.9×	52 0.6×	44 0.6×	7 0.1×	20	700
Peddagangannagari Sreekanthreddy India	5	155 0.9×	53 0.5×	70 0.8×	104 1.5×	22 0.4×	7	362
Xuesong Du China	11	103 0.6×	37 0.4×	78 0.8×	123 1.8×	8 0.1×	19	351
А. Yu. Lupatov Russia	12	149 0.9×	120 1.2×	26 0.3×	138 2.0×	22 0.4×	57	427
Kun Fan China	10	184 1.1×	104 1.0×	59 0.6×	19 0.3×	12 0.2×	16	391

Countries citing papers authored by Kelly Elian

Since Specialization

Citations

This map shows the geographic impact of Kelly Elian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelly Elian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelly Elian more than expected).

Fields of papers citing papers by Kelly Elian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelly Elian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelly Elian. The network helps show where Kelly Elian may publish in the future.

Co-authorship network of co-authors of Kelly Elian

This figure shows the co-authorship network connecting the top 25 collaborators of Kelly Elian. A scholar is included among the top collaborators of Kelly Elian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelly Elian. Kelly Elian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Elian, Kelly. (2020). Plasma Homocysteine and Vascular Disease. SHILAP Revista de lepidopterología. 2(2).

Drappatz, Jan, Andrew Brenner, Eric T. Wong, et al.. (2013). Phase I Study of GRN1005 in Recurrent Malignant Glioma. Clinical Cancer Research. 19(6). 1567–1576. 143 indexed citations

Kurzrock, Razelle, N. Gabrail, Chandtip Chandhasin, et al.. (2011). Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 11(2). 308–316. 138 indexed citations

Sarantopoulos, John, N. Gabrail, Stacy L. Moulder, et al.. (2010). ANG1005: Results of a phase I study in patients with advanced solid tumors and brain metastases.. Journal of Clinical Oncology. 28(15_suppl). 2556–2556. 10 indexed citations

Drappatz, Jan, Andrew Brenner, Steven S. Rosenfeld, et al.. (2009). Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma. Molecular Cancer Therapeutics. 8(12_Supplement). B160–B160. 1 indexed citations

Kurzrock, Razelle, Siqing Fu, Alain C. Mita, et al.. (2008). 424 POSTER ANG1005, an Angiopep-2/paclitaxel conjugate: the first clinical trial in patients with advanced cancer and brain metastases: Preliminary safety and tolerability data. European Journal of Cancer Supplements. 6(12). 133–133. 1 indexed citations

Castaigne, Jean‐Paul, Kelly Elian, S. Rosenfeld, et al.. (2008). 425 POSTER ANG1005: Preliminary clinical safety and tolerability in patients with recurrent malignant glioma. European Journal of Cancer Supplements. 6(12). 133–134. 1 indexed citations

Hoffer, L. John & Kelly Elian. (2004). Parenteral vitamin B12 therapy of hyperhomocysteinemia in end-stage renal disease.. PubMed. 27(1). 10–3. 16 indexed citations

Elian, Kelly & L. John Hoffer. (2002). Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism. 51(7). 881–886. 27 indexed citations

10.

Hoffer, L. John, et al.. (2001). Plasma reduced homocysteine concentrations are increased in end-stage renal disease. Kidney International. 59(1). 372–377. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact